<br>        Inclusion Criteria:<br><br>          -  infants 6 to 8 months old inclusive, who were born after full term pregnancy and<br>             previously received three doses of both Prevenar and Infanrix-hexa vaccines at least<br>             30 days before study entry<br><br>        Exclusion Criteria:<br><br>          -  who previously received any meningococcal vaccine;<br><br>          -  who have had a previous confirmed or suspected disease caused by N. meningitidis, C.<br>             diphtheriae, C. tetani, Poliovirus, Hepatitis B, Hib, Pneumococcus or B. pertussis;<br><br>          -  who have had household contact with and/or intimate exposure to an individual with<br>             laboratory confirmed N. meningitidis (serogroups A, C, W135, or Y), B. pertussis, Hib,<br>             C. diphtheriae, Polio, or pneumococcal infection at any time since birth;<br><br>          -  Subjects with any serious, acute or chronic progressive disease<br>      ;<br>        Inclusion Criteria:<br><br>          -  infants 6 to 8 months old inclusive, who were born after full term pregnancy and<br>             previously received three doses of both Prevenar and Infanrix-hexa vaccines at least<br>             30 days before study entry<br><br>        Exclusion Criteria:<br><br>          -  who previously received any meningococcal vaccine;<br><br>          -  who have had a previous confirmed or suspected disease caused by N. meningitidis, C.<br>             diphtheriae, C. tetani, Poliovirus, Hepatitis B, Hib, Pneumococcus or B. pertussis;<br><br>          -  who have had household contact with and/or intimate exposure to an individual with<br>             laboratory confirmed N. meningitidis (serogroups A, C, W135, or Y), B. pertussis, Hib,<br>             C. diphtheriae, Polio, or pneumococcal infection at any time since birth;<br><br>          -  Subjects with any serious, acute or chronic progressive disease<br>      ;<br>        Inclusion Criteria:<br><br>          -  infants 6 to 8 months old inclusive, who were born after full term pregnancy and<br>             previously received three doses of both Prevenar and Infanrix-hexa vaccines at least<br>             30 days before study entry<br><br>        Exclusion Criteria:<br><br>          -  who previously received any meningococcal vaccine;<br><br>          -  who have had a previous confirmed or suspected disease caused by N. meningitidis, C.<br>             diphtheriae, C. tetani, Poliovirus, Hepatitis B, Hib, Pneumococcus or B. pertussis;<br><br>          -  who have had household contact with and/or intimate exposure to an individual with<br>             laboratory confirmed N. meningitidis (serogroups A, C, W135, or Y), B. pertussis, Hib,<br>             C. diphtheriae, Polio, or pneumococcal infection at any time since birth;<br><br>          -  Subjects with any serious, acute or chronic progressive disease<br>      ;<br>        Inclusion Criteria:<br><br>          -  infants 6 to 8 months old inclusive, who were born after full term pregnancy and<br>             previously received three doses of both Prevenar and Infanrix-hexa vaccines at least<br>             30 days before study entry<br><br>        Exclusion Criteria:<br><br>          -  who previously received any meningococcal vaccine;<br><br>          -  who have had a previous confirmed or suspected disease caused by N. meningitidis, C.<br>             diphtheriae, C. tetani, Poliovirus, Hepatitis B, Hib, Pneumococcus or B. pertussis;<br><br>          -  who have had household contact with and/or intimate exposure to an individual with<br>             laboratory confirmed N. meningitidis (serogroups A, C, W135, or Y), B. pertussis, Hib,<br>             C. diphtheriae, Polio, or pneumococcal infection at any time since birth;<br><br>          -  Subjects with any serious, acute or chronic progressive disease<br>